SOURCE: Quture International, Inc.

Quture International, Inc.

May 09, 2013 10:00 ET

Quture (QUTR) Announces Commercial Release of First Application of QualOptima Product

Commercial Sales to Transition From Peer Review to Clinical Performance Analytics Application With Market Potential Exceeding $500 Million Annually

DAYTONA BEACH, FL--(Marketwired - May 9, 2013) - Quture International, Inc. (OTCQB: QUTR) announced today the launch of the first application of QualOptima for hospitals, physician groups, payers and regulators to transform peer review to clinical performance measurement and analytics. Commercial marketing and sales will begin in June for installations beginning in July. The technology for the cloud application of QualOptima is on the InterSystems platform now licensed by Quture. As previewed in the announcement on April 4, 2012, this initial QualOptima application is being launched following successful completion of the Clinical Trial at the University of Miami/Jackson Memorial Hospital (UoM) using the installation at Springhill Medical Center, Springhill, LA to test and evaluate the application's ROI and user advantages of this Connectivity & Analytics System. QualOptima is Quture's "transformative and disruptive" tool to enhance clinical performance to achieve optimal patient outcomes. 

The inherent limitations of peer review and compliance requirements for hospitals will be overcome through the electronic performance measurement technology proven at Demonstration Sites. The new peer review application in QualOptima will continue to advance peer review from anecdotal, unstructured and subjective to electronic, structured, and evidenced-based explicit analytics. The product will be introduced into the market for the peer review application. The market potential was originally estimated in excess of $500,000,000 in the United States alone. The healthcare analytics market is growing at 27% per year and is predicted to be $10.8 billion in 2015, so the market significantly exceeds this original projection. Quture continues to evaluate market penetration potentials, which the Company believes to be unlimited but in an increasingly competitive market.

"The core competence of Quture to measure and analyze clinical performance using extensive metrics developed for over 37 years is embedded in this QualOptima application," said Landon Feazell, CEO of Quture International. "Unlike competing products that rely on billing and administrative data, QualOptima captures clinical data electronically from existing disparate databases across the entire spectrum of third-party vendor products including electronic medical records. It is simply impossible to continue to add FTEs fast enough at dramatically increasing costs to comply with standards and regulations manually. The QualOptima system solves compliance challenges while implementing true enterprise management beyond business intelligence to empower clinical performance enhancement to achieve optimal patient outcomes."

Quture continues to collaborate with InterSystems engineers led by Quture's Chief Technology Officer Sherif Elfayoumy, Ph.D. working through the Company's technology partner Q'Zure, LLC with supplemental programming by Qatalys, Dallas, TX. The InterSystems tools of the Ensemble interface engine, Cache object-oriented database, DeepSee data display and Zen report writer are now strengthened by Active Analytics as the complete solution for performance and outcomes actionable insight. Commercial launch follows successful completion of evaluation of Quture's value proposition from data sets, mathematical modeling and algorithms developed from the Clinical Trial and experience with product performance at a real-world demonstration site with an existing customer. QualOptima delivers the product promise to provide data-driven solutions for results driven success in the emerging digital transformation of health care.

"The essential needs in healthcare for compliance with Joint Commission standards for Focused and Ongoing Professional Practice Evaluation (FPPE-OPPE), meaningful use (MU) and value-based purchasing (VBP) requirements by the federal government and now adopted by private healthcare insurance companies are met and exceeded by QualOptima," added Feazell. "Our technology and insight from years of lessons learned in the industry to market electronic tools are fundamental to the QualOptima solution. We can now offer our customers the technology and embedded clinical content to no longer measure clinical performance manually. QualOptima converts that labor-intensive process into an electronic system that provides real-time clinical knowledge and insight for doctors, nurses and hospitals as never before. Our years of developing clinical content and utilizing a new technology platform will finally achieve its potential. We believe our knowledge solutions, supported by our QualPRO expert panels of physicians and clinicians from every specialty, are vital to providers and payers. The system uses Quture's unique and extraordinary root cause analytics to improve clinical care and reduce costs. The ultimate value of clinical process improvements benefits patients in our continuing endeavors to improve quality, patient safety and clinical outcomes. This is yet another significant milestone in the evolution of Quture."

Quture continues to work through its own marketing and sales program as well as jointly with companies such as New Health Analytics, Richmond, VA as recently announced. Joint marketing and sales are augmented by combining other valuable product technologies and functionalities intended to dominate the healthcare analytics market.

ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As a "Breakthrough" Application Partner of InterSystems Corporation, Quture's technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company's unique product QualOptima develops a second generation CLINICAL database implementing Quture's core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

Contact Information

  • Contact:
    Mele Telitz
    Director of Communications
    855.740.QUTR (7878)
    mele@quture.com

    For Further Information Contact:
    Constellation Asset Advisors, Inc.
    Jens Dalsgaard
    President
    +1 (415) 524-8500

    and

    Infinity Advisors
    Mark Kroeger
    +1 (239) 495-6125